Baylor College of Medicine partners with BE to develop COVID-19 vaccine

BE, a Hyderabad-based has licensed the recombinant protein COVID-19 vaccine candidate developed at Baylor. The company engaged in license negotiations with the BCM Ventures team, part of Baylor College of Medicine

By   |  Business bureau  |  Published: 13th Aug 2020  5:17 pm

Hyderabad: Baylor College of Medicine based in Houston, Texas, US and Biological E Limited (BE) announced a licensing agreement for the development of a safe, effective and affordable COVID-19 vaccine.

BE, a Hyderabad-based has licensed the recombinant protein COVID-19 vaccine candidate developed at Baylor. The company engaged in license negotiations with the BCM Ventures team, part of Baylor College of Medicine, after initial discussions on Baylor’s technology and how it could possibly make a vaccine to address the current global pandemic. The company will leverage its past experience for the further development and commercialisation of the vaccine candidate, which is currently produced using a proven yeast-based expression technology.

“This week’s information that India has become the third-leading nation in terms of COVID-19 cases has sparked concern that COVID-19 will become widespread and a serious and deadly infection across the crowded urban areas of South Asia,” said Dr Peter Hotez, professor and dean of the National School of Tropical Medicine at Baylor and co-director of Texas Children’s Center for Vaccine Development. “This is why this agreement is timely.”

The current focus is on transfer of the technology for BE to initiate scale-up of the manufacturing process and undertake further development of the vaccine candidate.

“The partnership with Baylor would help accelerate the development of an affordable vaccine, especially for India and other low- and middle-income nations,” said Mahima Datla, managing director of BE.


Now you can get hand picked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .